Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75  years-old

Conclusion The risk of overexposure to erlotinib increases with age. Reduced lean body mass may explain erlotinib pharmacokinetics and excessive acute toxicity in the elderly.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research